Title :

Dose de-escalation to adalimumab 40?mg every three weeks in patients with inflammatory bowel disease-a multicenter, retrospective, observational study

Author(s) :

Pouillon, Lieven [Auteur]
Université de Lorraine [UL]
Lamoureux, Anne [Auteur]
Université de Lorraine [UL]
Pineton De Chambrun, Guillaume [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Vuitton, Lucine [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Pariente, Benjamin [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Zallot, Camille [Auteur]
Université de Lorraine [UL]
Dufour, Gaspard [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Fumery, Mathurin [Auteur]
Service d'Hépato Gastroenterologie [CHU Amiens-Picardie]
Baumann, Cedric [Auteur]
Plateforme d'Aide à la Recherche Clinique [CHRU Nancy] [PARC]
Amiot, Aurelien [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Nancey, Stephane [Auteur]
Hospices Civils de Lyon [HCL]
Rousseau, Helene [Auteur]
Plateforme d'Aide à la Recherche Clinique [CHRU Nancy] [PARC]
Peyrin-Biroulet, Laurent [Auteur]
Université de Lorraine [UL]

Journal title :

Digestive and Liver Disease

Abbreviated title :

Dig Liver Dis

Volume number :

51

Pages :

236-241

Publication date :

2019-02

ISSN :

1878-3562

English keyword(s) :

Inflammatory bowel disease
Crohn's disease
Adalimumab
De-escalation
Ulcerative colitis

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Data about the outcomes after adalimumab dose de-escalation in inflammatory bowel disease (IBD) are scarce. To assess the outcomes after adalimumab dose de-escalation, and to identify potential factors associated with ...
Show more >Data about the outcomes after adalimumab dose de-escalation in inflammatory bowel disease (IBD) are scarce. To assess the outcomes after adalimumab dose de-escalation, and to identify potential factors associated with failure. Retrospective, observational study including all IBD patients who had undergone adalimumab dose de-escalation to 40 mg every three weeks across seven GETAID centers, between June 2011 and September 2017. Failure of adalimumab dose de-escalation was defined as the need for treatment re-escalation, discontinuation of adalimumab, or clinical, biochemical and/or morphologic disease relapse. Fifty-six patients were identified (n = 46 Crohn's disease, n = 10 ulcerative colitis). Median (IQR) duration of follow-up after adalimumab dose de-escalation was 15.9 (7.9-30.6) months. Adalimumab dose de-escalation was a failure in 21/56 (37.5%) patients and successful in 35/56 (62.5%) patients. Median (IQR) time until failure was 8.9 (4.6-15.6) months. At multivariate analysis, inactive disease at magnetic resonance imaging and/or endoscopy in the year before adalimumab dose de-escalation decreased the risk of failure with a factor five (P = 0.02). Adalimumab dose de-escalation to 40 mg every three weeks is possible in almost two thirds of IBD patients. Objective morphologic signs of active disease should be ruled out before considering a de-escalation strategy with adalimumab.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T10:27:30Z
2024-04-08T12:52:15Z